Voluntary nationwide recall: Cyclobenzaprine (Unichem – August 2025)

Sep. 2025Pharmacy Updates

Unichem Pharmaceuticals (USA), Inc. is recalling one lot, lot GMML24026A, of Cyclobenzaprine Hydrochloride Tablets USP 10 mg. Cyclobenzaprine is used for the relief of muscle spasms from certain conditions.

This drug is being recalled because a Cyclobenzaprine 10 mg (90-count) label was accidentally placed on a bottle containing Meloxicam 7.5 mg tablets. Meloxicam is a nonsteroidal anti-inflammatory drug and is used for the treatment of certain types of arthritis. Meloxicam Tablets, USP, 7.5 mg are light yellow, round, flat, beveled-edged tablets with “U & L” debossed on one side and “7.5” debossed on the other side. Using Meloxicam unknowingly if it is not prescribed for you may cause any of several different serious adverse events—particularly in people taking other nonsteroidal anti-inflammatory drugs or blood thinners, people who have allergies to Meloxicam, or people with underlying illness.

To see if your medication was recalled, contact your doctor or pharmacy where you received it or visit the FDA website below. If you have an affected lot of Cyclobenzaprine, you should stop using the product and return it to the place of purchase. If you have experienced any problems that may be related to taking this product, you should contact your doctor or health care provider.

As of Aug. 27, there had been no reports of adverse events related to this recall.

To learn more about this recall, you can take one or more of the steps below.

  • Talk to your doctor or pharmacist.
  • Call Inmar at 1-877-840-5109. TTY users should call 711. Help is available Monday through Friday from 9 a.m. to 5 p.m. CST.
  • Visit the FDA website.

Recent Announcements

Medicaid Renewal

 Starting in 2027, some Medicaid recipients (ages 19–-64) will have new requirements to keep their coverage.
Aug. 2026Important Notices

Provider Directory Updates and Required Attestation

As you know, UPMC Health Plan requires all providers to verify their provider directory information at least every 90 days (quarterly).
Aug. 2026Important Notices

Voluntary nationwide recall: Tyenne (Fresenius – August 2026)

Fresenius Kabi is recalling one lot, lot 16UI07, of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL (20 mg/mL) 20 mL vials. Tyenne is used for the treatment of certain arthritis conditions.
Aug. 2026Pharmacy Updates